POM-V Prescription Required

Bovilis Bovipast RSP

Active ingredients: Bovine parainfluenza virus 3, Bovine respiratory syncytial virus, Mannheimia haemolytica

Form

Injection

Species

Cattle

Manufacturer

Intervet International B.V.

VMD MA No.

06376/3028

What it's used for

Cross-reactive immunity to the A6 serotype of Mannheimia haemolytica has been demonstrated in a challenge experiment under laboratory conditions after prim...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Bovine parainfluenza virus 3...

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Bovilis Bovipast RSP — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

Cross-reactive immunity to the A6 serotype of Mannheimia haemolytica has been
demonstrated in a challenge experiment under laboratory conditions after primary
course of vaccination.
Approximately two weeks after completion of the basic immunisation programme, the
humoral immune response against Bovine Respiratory Syncytial virus and
Parainfluenza-3 virus is at its highest level. The duration of protective immunity has
not been established in challenge experiments.
Onset of immunity: 2 weeks.
Duration of immunity: has not been established.

Dose:
5 ml.
Basic immunisation:
Animals from approximately 2 weeks of age should receive two vaccinations
separated by an interval of approximately 4 weeks.
Booster doses:
If booster doses are required, a single dose should be given approximately 2 weeks
before each risk period (e.g. transport, introduction into a herd, change of housing).
The vaccine must be shaken well before use.
For vaccine administration, needles of 1.5 to 2.0 mm diameter and 10 to 18 mm long
are recommended. The vaccine should be brought to room temperature prior to use
and injected quickly.

Do not vaccinate animals that have intercurrent disease, heavy parasitic infestation
or are in poor general condition, since a satisfactory immune response will only be
obtained in healthy and immuno-competent animals.

Cattle:
Common
(1 to 10 animals / 100 animals
treated):
Injection site swelling
.
Elevated temperature
, reluctant to move.
Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Hypersensitivity reaction
.
In extreme cases narrow swellings up to 10 cm long. Typically, these swellings
completely disappear or reduce in size to a negligible small lump within 2 to 3
weeks after vaccination, though in individual animals very small reactions can be
found for up to 3 months.
Slight and lasting a maximum of 3 days after vaccination.
May be fatal.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or the national competent authority via the
national reporting system. See the package leaflet for respective contact details.

Vaccinate healthy animals only.
The basic immunisation should be started in time, so that immunity has fully
developed by the beginning of the period of risk. The basic immunisation of calves
should be completed prior to housing or should be performed in the housing unit
under quarantine.
It is advisable to vaccinate all animals in a herd in order to minimise the infectious
potential unless there is a contraindication. Failure to vaccinate individual animals
may promote the transmission of pathogens and development of disease.
The magnitude of the antibody response may be reduced by maternally derived
antibodies in calves up to six weeks of age. However, according to the results of
challenge experiments, significant protection against infection by Bovine Respiratory
Syncytial virus is still provided three weeks after the basic vaccination course, and
significant protection against Parainfluenza-3 virus and Mannheimia haemolytica
serotype A1 is still provided six weeks after the basic vaccination course. The results
of challenge experiments in calves with maternally derived antibodies further indicate
that the onset of cross-protective immunity to the A6 serotype is 2 weeks after
completion of the vaccination course. Cross protective immunity is provided up to six
weeks after the basic vaccination course as demonstrated by serological tests.
Respiratory infections in calves are often associated with poor hygiene. Thus,
general improvements in hygiene are important to support the effect of vaccination.

Special precautions for safe use in the target species:
Not applicable.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
In case of accidental self-injection seek medical advice immediately and show the
package leaflet or the label to the physician.
Special precautions for the protection of the environment:
Not applicable.

Safety and efficacy data are available which demonstrate that this vaccine can be
administered on the same day but not mixed with Bovilis IBR Marker Live (where this
product is authorised) in cattle from 3 weeks of age onwards.
No information is available on the safety and efficacy of this vaccine when used with
any other veterinary medicinal product except the product mentioned above. A
decision to use this vaccine before or after any other veterinary medicinal product
therefore needs to be made on a case by case basis.
Immunosuppressive drugs should generally not be used directly before or after
vaccination, since a satisfactory immune response will only be obtained in immuno-
competent animals.

Store in a refrigerator (2 °C – 8 °C).
Protect from frost.
Protect from light.

Zero days.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.